lMiR-335 is involved in major depression disorder and antidepressant treatment through targeting GRM4
lMiR-335 is involved in major depression disorder and antidepressant treatment through targeting GRM4
复制标题
DOI：
10.1016/j.neulet.2015.08.038
复制
发表时间：
2015-10-08
影响因子：
2.5
通讯作者：
Qiu, Tian
中科院分区：
文献类型：
--
作者：
Li, Jing;Meng, Huaqing;Qiu, Tian
重度抑郁症（MDD）是一种普遍存在的情绪障碍。 MDD 的治疗包括多种生物心理社会方法。谷氨酸受体代谢型 4 (GRM4) 与 MDD 的调节有关，它被视为药物发现和开发的一个有吸引力的靶点。在这里，我们使用 MDD 患者的细胞测定和血液样本进行报告，结果表明，与健康对照相比，抑郁症患者的 miR-335 下调。此外，我们证实miR-335可以直接靶向GRM4，从而进一步调控miR-335的表达。西酞普兰抗抑郁药物治疗可以上调 miR-335 表达并下调 GRM4 表达。这些结果表明 miR-335 与抑郁症的病理生理学相关，并且是新的抗抑郁治疗的潜在靶点。 (C) 2015 Elsevier Ireland Ltd. 保留所有权利。
Major depressive disorder (MDD) is a prevalent mood disorder. Treatment of MDD includes a variety of biopsychosocial approaches. Glutamate receptor, metabotropic 4 (GRM4) has been implicated in the regulation of MDD and it is seen as an attractive target for drug discovery and development. Here we reported using cellular assays and blood samples from MDD patients and showed that miR-335 was downregulated in individuals with depression compared with healthy controls. Additionally, we confirmed that miR-335 can directly target GRM4, which can further regulated the expression of miR-335. Antidepressant drug treatment with citalopram can upregulate miR-335 expression and downregulate GRM4 expression. These results suggest that miR-335 is associated with the pathophysiology of depression and is a potential target for new antidepressant treatments. (C) 2015 Elsevier Ireland Ltd. All rights reserved.